OBParp 150mg Tablet

About

OBParp 150mg Tablet is an oral poly (ADP-ribose) polymerase (PARP) inhibitor, a class of targeted therapy used in oncology. It works by blocking PARP enzymes, which are crucial for repairing single-strand DNA breaks in cells. In cancer cells with existing DNA repair defects, particularly those with homologous recombination repair deficiencies like BRCA mutations, inhibiting PARP leads to an accumulation of unrepaired DNA damage. This extensive damage triggers a process known as synthetic lethality, ultimately causing the cancer cells to die while sparing healthy cells to a greater extent. This precise mechanism makes OBParp highly effective in treating specific types of cancers where DNA repair pathways are already compromised, offering a significant advancement in precision oncology by targeting the inherent vulnerabilities of malignant cells.

Uses

• Maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
• Treatment of BRCA-mutated HER2-negative metastatic breast cancer.
• Treatment of germline BRCA-mutated metastatic pancreatic adenocarcinoma.
• Treatment of homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.

Directions For Use

Take OBParp 150mg Tablet orally, usually twice daily, with or without food, as directed by your oncologist. Do not crush, chew, or split the tablets.

Benefits

• Targets specific DNA repair pathways in cancer cells.
• Effective in BRCA-mutated cancers.
• Offers a maintenance therapy option for ovarian cancer.
• Improves progression-free survival in eligible patients.
• Oral administration for convenience.
• Part of a precision medicine approach.

Side Effects

• Nausea
• Fatigue
• Vomiting
• Anemia
• Diarrhea
• Decreased appetite
• Abdominal pain
• Constipation
• Headache
• Myelosuppression (low blood counts)
• Pneumonitis
• Secondary malignancies (e.g., MDS/AML)

Safety Measures

• Alcohol - Limit or avoid alcohol consumption as it may exacerbate certain side effects or interact with the medication. Consult your doctor.
• Pregnancy - OBParp is contraindicated in pregnancy due to potential fetal harm. Effective contraception must be used during treatment and for a period after.
• Breastfeeding - Breastfeeding is not recommended during treatment with OBParp and for one month after the last dose, due to potential harm to the infant.
• Liver - Use with caution in patients with hepatic impairment. Dose adjustments may be necessary based on the severity of liver dysfunction.
• Kidney - Dose adjustments may be required for patients with moderate or severe renal impairment. Close monitoring is essential.
• Lung - Rare cases of pneumonitis have been reported. Monitor for new or worsening respiratory symptoms.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.